Pyruvate kinase deficient hemolytic anemia in the Northern Irish population

M J Percy1, R van Wijk, S Haggan

  • 1Department of Haematology, Floor C, Tower Block, Belfast City Hospital, Lisburn Road, Belfast, BT9 7AB, Northern Ireland. melanie.percy@bll.n-i.nhs.uk

Insights

Pyruvate kinase deficiency, a cause of hereditary hemolytic anemia, was investigated in Northern Ireland, identifying six new mutations and seven total patients. This suggests many cases may go undiagnosed due to mild anemia.

Area of Science:

  • Hematology
  • Genetics
  • Biochemistry

Background:

  • Pyruvate kinase deficiency (PKD) is a common cause of hereditary nonspherocytic hemolytic anemia.
  • It is inherited autosomally and has a worldwide distribution, with higher prevalence in Caucasian populations.
  • Over 180 mutations in the PKLR gene have been described.

Purpose of the Study:

  • To investigate pyruvate kinase deficiency cases in Northern Ireland.
  • To identify novel mutations and understand the genetic landscape of PKD in this population.

Main Methods:

  • Molecular investigation of patients with hemolytic anemia.
  • Identification and characterization of mutations in the PKLR gene.

Main Results:

  • Four new cases of pyruvate kinase deficiency were identified in Northern Ireland.
  • A total of six different mutations were found, including one novel homozygous mutation (p.Arg495Val).
  • Nine mutant PKLR alleles were identified across seven Irish patients, indicating no single founder mutation.

Conclusions:

  • The study identified new cases and mutations of pyruvate kinase deficiency in Northern Ireland.
  • The findings suggest a lack of a founder mutation in the Northern Ireland population.
  • Undiagnosed mild cases of pyruvate kinase deficiency may contribute to its underrepresentation in the region.

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Translation01:31

Translation

Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life